X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.040
+0.010 (0.25%)
At close: Aug 21, 2026, 4:00 PM EDT
4.127
+0.087 (2.15%)
After-hours: Aug 21, 2026, 7:30 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $8.81M in the quarter ending June 30, 2026, with 346.33% growth. This brings the company's revenue in the last twelve months to $15.85M, down -51.65% year-over-year. In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth.
Revenue (ttm)
$15.85M
Revenue Growth
-51.65%
P/S Ratio
25.28
Revenue / Employee
$352,156
Employees
45
Market Cap
400.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 59.22M |
| vTv Therapeutics | 36.84M |
| Foghorn Therapeutics | 36.74M |
| Arcturus Therapeutics Holdings | 29.37M |
| Upstream Bio | 3.16M |
| Lyell Immunopharma | 27.00K |
XFOR News
- 15 days ago - X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c) - TheFly
- 15 days ago - X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - X4 Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 16 days ago - X4 Pharmaceuticals Earnings release: Q2 2026 - Filings
- 18 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - X4 Pharmaceuticals initiated with an Overweight at Wells Fargo - TheFly
- 6 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board - TheFly